Shamburg News · 8-K filed Nov 4, 2026, 5:10 PM EST

Evommune Licenses VAV1 Degrader EVO570 from Hinova and Launches $30M Private Placement

EVMN · Evommune, Inc.

  • Material agreement
  • Financing
  • Acquisition
  • Reg FD disclosure
  • Other event
  • Materiality: high

On November 4, 2026, Evommune entered into an exclusive license agreement with Hinova Pharmaceuticals for worldwide rights outside Greater China to the VAV1 degrader EVO570, paying a $20.0 million upfront cash payment and issuing pre-funded warrants valued at $10.0 million, with up to $150.0 million in development and regulatory milestones, up to $920.0 million in commercial milestones, and tiered royalties. The same day, Evommune agreed to sell 4,966,889 common shares at $6.04 per share in a private placement, with gross proceeds expected to be approximately $30.0 million and closing expected on or about November 6, 2026. The company also estimated preliminary cash, equivalents and investments plus private placement proceeds of approximately $292.3 million, sufficient to fund operations into the second half of 2029.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 3.02, 7.01, 8.01, 9.01, accession 0001193125-26-447608.

Written from the filing by Shamburg Markets. Figures are as reported by the company.